Finch M B, Dawson J, Johnston G D
Clin Rheumatol. 1986 Dec;5(4):493-8.
The effectiveness of nifedipine in the treatment of Raynaud's syndrome was assessed in 16 patients with systemic sclerosis or a variant of this condition. Changes in finger and forearm blood flow (venous occlusion plethysmography), skin temperature and digital systolic pressure were measured both during the acute period and after a 2-week treatment. Subjective assessment of efficacy was based on patient diary data. Finger blood flow increased significantly both during the acute period and after 2 weeks of nifedipine therapy compared to placebo (P less than 0.05). Digital skin temperature also increased during the study period (P less than 0.01). Forearm blood flow and digital systolic pressure did not change. Nifedipine significantly reduced the frequency (P less than 0.05), duration (P less than 0.05) and severity (P less than 0.01) of attacks. Eleven out of the sixteen patients experienced side effects while on nifedipine. These results suggest that nifedipine is of benefit in the treatment of Raynaud's syndrome in patients with systemic sclerosis over a short time course.
对16例系统性硬化症患者或其变异型患者评估了硝苯地平治疗雷诺综合征的疗效。在急性期和2周治疗后,均测量了手指和前臂血流量(静脉阻塞体积描记法)、皮肤温度和指动脉收缩压。疗效的主观评估基于患者日记数据。与安慰剂相比,硝苯地平治疗2周后,急性期和治疗后手指血流量均显著增加(P<0.05)。在研究期间,指部皮肤温度也升高(P<0.01)。前臂血流量和指动脉收缩压未发生变化。硝苯地平显著降低了发作频率(P<0.05)、持续时间(P<0.05)和严重程度(P<0.01)。16例患者中有11例在服用硝苯地平期间出现了副作用。这些结果表明,硝苯地平在短期内对系统性硬化症患者的雷诺综合征治疗有益。